Alerta

SARS-CoV-2 Binding Polypeptide

Resumen de: US20260176302A1

The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of polypeptides.

DIARYL HYDANTOIN COMPOUNDS AND USES THEREOF

Resumen de: WO2026132293A1

Advantageous specific symmetric diaryl hydantoin compounds are provided that have surprising activity as protease inhibitors against the main protease of coronavirus (MPRO), and thus can be used to treat a host in need thereof with a coronavirus including the SARS CoV-2 virus or a seasonal coronavirus in a host.

CELL-BASED FORMULATION CONTAINING PLURIPOTENT STEM CELLS FOR DISEASES OR POST-ACUTE SEQUELAE CAUSED BY SARS-COV-2 INFECTION

Resumen de: WO2026133815A1

This cell-based formulation contains SSEA-3-positive pluripotent stem cells derived from mesenchymal tissue of a living body or derived from cultured mesenchymal cells. This cell-based formulation is characterized in that the formulation is for administration to address diseases and/or post-acute sequelae caused by SARS-CoV-2 infection. The present invention makes it possible to provide a cell-based formulation that contains pluripotent stem cells and is used for treating and/or preventing SARS-CoV-2 infection-caused diseases such as pneumonia and pulmonary fibrosis and SARS-CoV-2 infection-caused post-acute sequelae such as olfactory dysfunctions.

NANOBODY-BASED LATERAL FLOW IMMUNOASSAY FOR RAPID ANTIGEN DETECTION

Resumen de: WO2026133305A2

A nanobody-based point-of-care lateral flow immunoassay (LFA) for the rapid, cost-effective detection of SARS-CoV-2 and MERS-CoV proteins in biological samples is disclosed. The assay described herein uses nanobody-based binding agents that selectively capture and detect viral antigens, such as spike (S) proteins and receptor-binding domains (RBDs), with high sensitivity and specificity. The LFA utilizes a colorimetric readout visible to the naked eye, eliminating the need for specialized equipment. The assay supports single and multiplex detection formats, enabling simultaneous analysis of multiple viral analytes. The LFAs are stable under standard storage conditions and provide a practical solution for decentralized and scalable testing.

SINGLE-DOMAIN ANTIBODIES INHIBITING VIRAL RNA POLYMERASE ACTIVITY

Resumen de: WO2026131760A1

The present invention relates notably to specific single-domain antibodies (sdAbs) targeting RNA-dependent RNA polymerase (RdRp) activity and their use in the prevention and/or treatment of a virus infection from Coronaviruses, and more particularly of SARS-CoV-2.

Treatment for Coronavirus infection and associated cytokine toxicity

Resumen de: AU2026204379A1

The present invention relates to novel methods comprising the administration of pentosan polysulfate for treating or preventing coronavirus infection and cytokine- associated toxicity, including cytokine toxicity resulting from aberrant activation of the immune system in coronavirus disease or infection, such as those from SARS-CoV-2. 5 un u n

NUCLEASE-DENDRIMER FORMULATIONS FOR COVID-19 AND BROAD-SPECTRUM ANTIVIRAL THERAPY AND PROPHYLAXIS

Resumen de: US20260174873A1

Compositions of nucleases in formulations with dendrimers are used in pharmaceutically effective dosages as therapeutics for covid-19 and a broad spectrum of viruses in various embodiments. When cationized nucleases are mixed and/or complexed with a dendrimer, an unexpected positive dendrimer effect is manifest. This positive dendrimer effect is shown to be highly effective for catalyzing anti-viral RNase properties. In various embodiments compositions of cationized nucleases in combination with a dendrimer demonstrated this synergistic amplification of anti-viral effectiveness and are used in pharmaceutically effective dosages as therapeutics against covid-19 and a broad spectrum of viruses. An exemplar formulation which exhibits a positive dendrimer effect is cationized RNase A mixed and/or complexed with gen 2 PAMAM dendrimer.

Anti-SARS-CoV-2 antibodies and uses thereof

Resumen de: AU2026204287A1

The present disclosure relates to proteins which bind to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. un u n

ANTISENSE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS AGAINST SARS COV-2

Resumen de: EP4763985A1

The present invention concerns the creation of antisense oligonucleotides (ASOs) with no cytotoxicity that are very active as therapeutic agents in knocking down the replication of SARS-CoV-2 in human cells with pan activity against all known past and current variants.

2 Binding Molecule Specific to SARS coronavirus 2 variants spike protein and its uses

Resumen de: KR20260095805A

본 발명은 사스 코로나 바이러스 2 변이체의 스파이크 단백질에 특이적인 결합 분자 및 이의 용도에 관한 것이다. 보다 구체적으로는, 본 발명의 결합 분자는 사스 코로나 바이러스 2(SARS-CoV-2) 변이체의 스파이크 단백질(Spike protein)의 RBD(Receptor binding domain) 영역에 특이적인 결합 능력을 가지고, 사스 코로나 바이러스 감염증에 대한 치료제와 비교하여 우수한 중화 활성을 나타냄을 확인하였는 바, 사스 코로나 바이러스 감염증에 대한 예방 또는 치료에 활용될 수 있다.

CORONAVIRUS VACCINE

Resumen de: AU2024380373A1

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

( E)-5-ALKOXY-1-PHENYLPENTAN-1-ONE O-(2-( N, N- DISUBSTITUTED AMINO)ETHYL) OXIMES AND THEIR THERAPEUTIC USE FOR COVID-19 DISEASE

Resumen de: WO2026126237A1

The present invention relates to (E)-5-alkoxy-1- phenylpentan-1-one O-(2-(N,N- disubstitutedamino)ethyl) oximes and the methods of preparation thereof. The present invention describes the (E)-5-alkoxy-1-phenylpentan-1-one O-(2-(N,N- disubstitutedamino)ethyl) oximes as potent anti-COVID-19 agent.

MONOCLONAL ANTIBODIES SPECIFIC FOR FAS LIGAND AND USES THEREOF

Resumen de: US20260167734A1

Monoclonal antibodies that specifically bind to and block the function of Fas ligand (FasL) are described. The FasL-specific antibodies can be used for the development of therapeutics for the treatment of diseases, disorders and conditions associated with the Fas/FasL signaling pathway, such as cancer, sepsis, ischemia-reperfusion injury, and coronavirus disease 2019 (COVID-19).

PROTACS TARGETING VIRAL ENZYMES FOR PRECISE TREATMENT OF COVID-19

Resumen de: US20260166160A1

Described are proteolysis targeting chimeras (PROTACs) for use in managing and treating infectious disease. Described compositions can be used to inhibit viral replication associated with coronavirus, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus disease 2019 (COVID-19). Methods of synthesizing PROTACs are described. Example PROTAC compositions are provided, including dual targeting compounds having a main protease (Mpro) ligand attached to a linker, an E3 ligase ligand attached to the linker, and a papain-like protease (PLpro) inhibitor attached to the linker. PROTAC compounds useful for degrading Mpro activity and/or PLpro activity, and useful for treating coronavirus infections such as COVID-19, are described.

MERS VACCINE ANTIGEN

Resumen de: WO2026123076A1

The field of the specification relates broadly to Middle East respiratory syndrome coronavirus vaccine (MERS-CoV) antigens and methods of using and manufacturing MERS-CoV antigens. The invention also relates to vaccines, kits, devices and strips comprising the MERS-CoV antigen. The invention also relates to ribonucleic acids encoding a S protein monomer of a coronavirus vaccine (MERS-CoV) antigen and methods of using and manufacturing the ribonucleic acid. The invention also relates to vectors, lipid nanoparticles, RNA vaccines, kits, devices and strips comprising the ribonucleic acid.

ACE2 HOMOLOGOUS PEPTIDE SEQUENCES

Resumen de: US20260167674A1

Peptide sequences that are ACE2 homologues are provided. Compared to the wild-type ACE2 in the host, the peptide sequences bind with higher affinity to the receptor-binding domain (RBD), thus inhibiting this interaction by competitively inhibiting the binding of the virus RBD region of SARS-COV-2 with the human ACE2. The peptide sequences can be included in a pharmaceutical composition.

PROTEIN, ADENOVIRUS AND VACCINE AGAINST INFECTION OF SUBTYPE OF SARS-COV-2 OMICRON MUTANT STRAIN XBB

Resumen de: EP4759833A1

The present invention relates to proteins, adenoviruses and vaccines against infection by SARS-CoV-2 Omicron XBB subvariants, which belongs to the medicine field. To address the lack of effective prophylactic and therapeutic drugs for preventing and/or treating infections by SARS-CoV-2 Omicron XBB variants and subvariants thereof, the present invention provides proteins, adenoviruses and vaccines for preventing and/or treating infection by SARS-CoV-2 Omicron XBB subvariants, wherein these vaccines are optimized and designed based on a full-length S protein, and the receptor-binding domain (RBD) and receptor-binding domain and heptad repeat (RBD-HR) sequences in the S protein of the SARS-CoV-2 Omicron XBB subvariants, specifically, XBB.1.16, XBB.1.5, XBB.1.16.6, BA.2.86, EG.5, JN.1, XBB.2.3 and XBB.2, and are capable of aiding the host in combating coronavirus infections, and particularly have a relatively good preventive and therapeutic effect against cross-infections caused by SARS-CoV-2 Omicron XBB subvariants.

NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS

Resumen de: EP4759827A2

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

SARS-COV-2 ANTIBODIES AND METHODS OF USING THE SAME

Resumen de: WO2023209177A1

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.

A SPATIOTEMPORAL DEEP LEARNING MODEL FOR FORECASTING THE DEVELOPMENT OF SUDDEN EPIDEMICS MODIFIED BY HISTORICAL METEOROLOGICAL DATA

Resumen de: LU604195B1

This invention discloses a spatiotemporal deep learning model for forecasting the development of sudden epidemics, taking into consideration meteorological factors. The method formulates the short-term prediction problem of regional new COVID-19 cases as a predictive technical issue involving multidimensional, gridded spatiotemporal sequences for both input and prediction targets. To address this, a ConvLSTM spatiotemporal deep model is constructed for predicting COVID-19 case numbers. Furthermore, the model is enhanced by considering the modifying effects of meteorological elements, creating a comprehensive spatiotemporal model called the Meteor-ConvLSTM model that integrates historical meteorological factors. This spatiotemporal model produces timely, downscaled, and high-resolution prediction results. This invention is characterized by high predictive accuracy and strong practicality, making it useful for guiding relevant authorities in understanding the epidemic situation and adjusting decision-making strategies.

VARIANT STRAIN-BASED CORONAVIRUS VACCINES AND USES THEREOF

Resumen de: US20260158135A1

0000 The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.

COMPOSITIONS SUITABLE FOR USE IN A METHOD FOR ELICITING CROSS-PROTECTIVE IMMUNITY AGAINST CORONAVIRUSES

Resumen de: US20260158134A1

Immunogenic compositions and methods of use thereof, for eliciting an immune response against multiple coronaviruses, using a single vaccine composition are described. The compositions include an antigen from more than one pathogen, for example, more than one member of the β-coronavirus family, for example, SARS-CoV and MERS-CoV. Exemplary antigens include the receptor binding domain (RBD) of the coronavirus spike protein or a fragment thereof. The disclosed compositions are administered to a subject in need therefore, to generate an immune response against more than one pathogen, represented by the source of the antigens in the construct.

MULTICISTRON EXPRESSION VECTOR FOR COVID-19 VACCINE

Resumen de: US20260159553A1

The present invention provides an expression vector comprises gene of interest encode more than one structural protein to enhance immune responses against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) and its variants. Furthermore, the expression vector to produce mRNA expresses more than one structural protein to generate immune response against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) and its variants.

PHARMACEUTICAL COMPOSITION, ITS USE AS A DRUG AND NEW COMPOUNDS, ESPECIALLY FOR TREATING SARS-COV-2 INFECTION

Resumen de: US20260158015A1

The present invention relates to a compound comprising a compound having formula (I) below:wherein R1, R2 and R3 are as defined, or a pharmaceutically acceptable salt thereof, for use in the prevention or in the treatment of an infection.The invention also relates to a pharmaceutical composition comprising the compound, for use in the prevention or in the treatment of an infection.

VIRAL INACTIVATION SPRAY AND GARGLING FORMULATION

Nº publicación: US20260157987A1 11/06/2026

Solicitante:

JAVIER RENE DUMALAOG [US]
Javier Rene Dumalaog

Resumen de: US20260157987A1

A viral inactivation composition includes an aqueous solution of citric acid and L-arginine hydrochloride with a pH below 3.5. The citric acid and L-arginine hydrochloride are present in amounts that directly inactivate COVID-19, influenza, and common cold virus in a human upper respiratory system. A method of directly inactivating COVID-19, influenza, and common cold virus in the human upper respiratory system includes administering the viral inactivation composition to a subject. These ingredients are safe, non-toxic, and very effective.